OptimizeRx revenue falls 10% as major customer goes dark; margin expansion drives near-breakeven

Filed May 13, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 13, 2025 · ~2 min read

Key Changes

• high

  Revenue declined 10% YoY to $19.8M as company exited low-margin managed service program and lost a customer representing ~10% of fiscal 2025 revenue. Master service agreement remains in place but future revenue uncertain.

  MD&A: Revenue verify on EDGAR →
• high

  Net loss narrowed 77% to $(495K) from $(2.2M) despite revenue decline, driven by gross margin expansion to 75% from 61%. Company shifted focus to higher-margin solutions after exiting DTC managed service program in Q3 2025.

  MD&A: Profitability verify on EDGAR →
• medium

  Board authorized $10M share repurchase program effective March 12, 2026, expiring March 15, 2027. Repurchases will be made opportunistically using available cash depending on market conditions and share price.

  MD&A: Capital Allocation verify on EDGAR →